Ultra Market Research | United Kingdom Methotrexate Solution Market
United Kingdom Methotrexate Solution Market
Report ID : 985
Category : Therapeutic-Area,United-Kingdom(UK)
No Of Pages : 88
Published on: February 2025
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
United Kingdom Methotrexate Solution Market
Introduction Methotrexate is a chemotherapy and immunosuppressive drug used for various types of cancer and autoimmune diseases like rheumatoid arthritis, psoriasis, and Crohn's disease. The UK methotrexate solution market involves oral and injectable formulations addressing an increasing number of patients that need effective, long-term solutions for managing the disease. Recent market trends have included an increase in demand for ready-to-use formulations to improve patient compliance and reduce the potential for administration errors. The development of pre-filled syringes and auto-injectors has been a major innovation, and home-based treatment is now possible. The United Kingdom Methotrexate Solution Market is expected to reach around USD 250 million by 2025, at a CAGR of 3.5% over the next five years. The growth of the market can be attributed to the increasing prevalence of rheumatoid arthritis (over 430,000 patients in the UK) and the growing incidence of cancer, hence maintaining the demand for methotrexate solutions.
Segmentation By Dosage Form • Oral Solutions o Concentration Variants 2.5 mg/ml 2 mg/ml Others o Packaging Types Bottles Pre-filled Syringes o Patient Demographics Pediatric Adult o Others • Injectable Solutions o Administration Routes Intravenous (IV) Intramuscular (IM) o Concentration Variants 25 mg/ml 50 mg/ml o Packaging Types Vials Ampoules o Others
By Application • Cancer Treatment o Cancer Types Leukemia Lymphoma Others o Treatment Settings Hospitals Specialty Clinics o Patient Demographics Pediatric Adult o Others • Autoimmune Diseases o Disease Types Rheumatoid Arthritis Psoriasis Others o Treatment Settings Hospitals Outpatient Clinics o Patient Demographics Pediatric Adult o Others
By Distribution Channel • Hospital Pharmacies o Ownership Types Public Private o Geographical Locations Urban Rural o Others • Retail Pharmacies o Store Formats Chain Pharmacies Independent Pharmacies o Geographical Locations Urban Rural o Others • Online Pharmacies o Service Models Direct-to-Consumer B2B Distribution o Others
List of Market Players 1. Pfizer Inc. (USA) 2. Hikma Pharmaceuticals (UK) 3. Teva Pharmaceuticals (Israel) 4. Accord Healthcare (UK) 5. Novartis AG (Switzerland) 6. Mylan (USA) 7. Sun Pharmaceutical Industries Ltd. (India) 8. Amneal Pharmaceuticals (USA) 9. Dr. Reddy’s Laboratories (India) 10. Sandoz (Germany) 11. Baxter International (USA) 12. Medac Pharma (Germany) 13. Hospira (USA) 14. Sanofi (France) 15. Aspen Pharmacare (South Africa)
Drivers United Kingdom Methotrexate Solution Market has several driving factors, including the increasing incidence of autoimmune disease and cancer. Methotrexate solution is considered as the prescription treatment option for rheumatoid arthritis and most types of cancers, thus creating a steady demand in the market. Additionally, drug delivery technology has helped increase the use of pre-filled syringes and auto-injectors in the market, further reduces medication errors and increases patient compliance. The UK is also experiencing an increasing geriatric population, which is expected to reach 15.7 million by 2030. Older adults are more prone to conditions that require methotrexate. In addition, the rise of online pharmacies has increased access, making methotrexate solutions more accessible.
Restraints Though growing, the UK Methotrexate Solution Market is not immune to problems and is majorly affected by strong regulatory policies enforced by the MHRA. A long process and high cost involved in getting products approved create further hurdles for product launches. The side effects associated with methotrexate include liver toxicity, bone marrow suppression, and gastrointestinal complications, among others, that force some patients to discontinue the treatment. The market also faces supply chain disruptions and price pressures, with the UK government regulating drug prices under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), capping profit margins for pharmaceutical firms.
Opportunities Rising adoption of biosimilars would lead to the most significant growth opportunities in the UK Methotrexate Solution Market. Biosimilar methotrexate solutions offer cheaper alternatives, and these will find a market place considering NHS cost-cutting initiatives. Another promising avenue is increasing research and development into targeted methotrexate therapies, such as liposomal formulations and nanotechnology-based delivery systems. This is because of the increased demand for home-based care, especially with the use of self-administered methotrexate injections in treating rheumatoid arthritis. The government reimbursement policies to reduce hospital visits also support this trend.
Trends One of the recent trends in the United Kingdom Methotrexate Solution Market is the personalization of the treatment, wherein genetic profiling aids in tailoring methotrexate dosages for individual patients to minimize side effects and maximize efficacy. The use of e-prescriptions and telemedicine has eased the involvement of methotrexate solutions in patients' treatments and decreased the dependence on face-to-face consultations. Other trends that are really worth mentioning include sustainable packaging with regard to reducing medical wastes, investment in biodegradable vials, and syringes by companies.
Approved & Pipeline Products • Approved Products o Metoject® (Medac Pharma) o Trexall® (Teva Pharmaceuticals) o Rheumatrex® (Pfizer) o Maxtrex® (Aspen Pharmacare) • Pipeline Products o Liposomal Methotrexate Solution o Nanoformulated Methotrexate
Rising prevalence of autoimmune diseases and cancer, increased adoption of self-injectable methotrexate, and NHS reimbursement policies.
Pfizer, Hikma Pharmaceuticals, Teva, Accord Healthcare, and Novartis.
Strict MHRA regulations, side effects of methotrexate, and pricing pressures.
Personalized medicine, telemedicine, biosimilars, and sustainable packaging.
Pre-filled syringes, auto-injectors, and oral solutions with higher bioavailability.
1. Introduction 1.1 Report Description 1.2 Research Methodology 1.2.1 Data Mining 1.2.2 Market Modeling and Forecasting 1.2.3 Data Validation 1.2.4 Industry Analysis
2. Market Dashboard
3. Market Overview 3.1 Market Definition and Scope 3.2 Market Segmentation 3.2.1 By Dosage Form • Oral Solutions o Concentration Variants 2.5 mg/ml 2 mg/ml Others o Packaging Types Bottles Pre-filled Syringes o Patient Demographics Pediatric Adult o Others • Injectable Solutions o Administration Routes Intravenous (IV) Intramuscular (IM) o Concentration Variants 25 mg/ml 50 mg/ml o Packaging Types Vials Ampoules o Others 3.2.2 By Therapeutic Application • Cancer Treatment o Cancer Types Leukemia Lymphoma Others o Treatment Settings Hospitals Specialty Clinics o Patient Demographics Pediatric Adult o Others • Autoimmune Diseases o Disease Types Rheumatoid Arthritis Psoriasis Others o Treatment Settings Hospitals Outpatient Clinics o Patient Demographics Pediatric Adult o Others 3.2.3 By Distribution Channels • Hospital Pharmacies o Ownership Types Public Private o Geographical Locations Urban Rural o Others • Retail Pharmacies o Store Formats Chain Pharmacies Independent Pharmacies o Geographical Locations Urban Rural o Others • Online Pharmacies o Service Models Direct-to-Consumer B2B Distribution o Others 3.3 Market Dynamics 3.3.1 Drivers 3.3.2 Restraints 3.3.3 Opportunities 3.3.4 Challenges
4. United Kingdom Methotrexate Solution Market by Dosage Form 4.1 Introduction 4.2 Market Size and Growth Rate by Dosage Form (2024-2030) 4.2.1 Oral Solutions 4.2.2 Injectable Solutions
5. United Kingdom Methotrexate Solution Market by Therapeutic Application 5.1 Introduction 5.2 Market Size and Growth Rate by Therapeutic Application (2024-2030) 5.2.1 Cancer Treatment 5.2.2 Autoimmune Diseases
6. United Kingdom Methotrexate Solution Market by Distribution Channels 6.1 Introduction 6.2 Market Size and Growth Rate by Distribution Channels (2024-2030) 6.2.1 Hospital Pharmacies 6.2.2 Retail Pharmacies 6.2.3 Online Pharmacies
7. Competitive Landscape 7.1 Company Profiles 7.1.1 Pfizer Inc. (USA) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 7.1.2 Hikma Pharmaceuticals (UK) 7.1.3 Teva Pharmaceuticals (Israel) 7.1.4 Accord Healthcare (UK) 7.1.5 Novartis AG (Switzerland) 7.1.6 Mylan (USA) 7.1.7 Sun Pharmaceutical Industries Ltd. (India) 7.1.8 Amneal Pharmaceuticals (USA) 7.1.9 Dr. Reddy’s Laboratories (India) 7.1.10 Sandoz (Germany) 7.1.11 Baxter International (USA) 7.1.12 Medac Pharma (Germany) 7.1.13 Hospira (USA) 7.1.14 Sanofi (France) 7.1.15 Aspen Pharmacare (South Africa)
10. Appendix 10.1 List of Tables & Figures List of Tables • Table 1: United Kingdom Methotrexate Solution Market Size & Growth Rate (2024-2030) • Table 2: Market Segmentation by Dosage Form, Therapeutic Application, and Distribution Channels • Table 3: Leading Market Players & Market Share Distribution • Table 4: Approved & Pipeline Methotrexate Products
List of Figures • Figure 1: United Kingdom Methotrexate Solution Market Revenue Forecast (2024-2030) • Figure 2: Market Share by Dosage Form (2024) • Figure 3: Market Share by Therapeutic Application (2024) • Figure 4: Distribution Channel Market Share Analysis (2024) • Figure 5: Competitive Landscape – Revenue Contribution of Leading Players
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done, and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of United Kingdom market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of United Kingdom Methotrexate Solution Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of United Kingdom Methotrexate Solution Market for the past year and forecasts for the next six years. United Kingdom Methotrexate Solution Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different United Kingdom Methotrexate Solution Market categories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for United Kingdom Methotrexate Solution Market from different application industries in different regions.
Segmentation By Dosage Form • Oral Solutions o Concentration Variants 2.5 mg/ml 2 mg/ml Others o Packaging Types Bottles Pre-filled Syringes o Patient Demographics Pediatric Adult o Others • Injectable Solutions o Administration Routes Intravenous (IV) Intramuscular (IM) o Concentration Variants 25 mg/ml 50 mg/ml o Packaging Types Vials Ampoules o Others
By Application • Cancer Treatment o Cancer Types Leukemia Lymphoma Others o Treatment Settings Hospitals Specialty Clinics o Patient Demographics Pediatric Adult o Others • Autoimmune Diseases o Disease Types Rheumatoid Arthritis Psoriasis Others o Treatment Settings Hospitals Outpatient Clinics o Patient Demographics Pediatric Adult o Others
By Distribution Channel • Hospital Pharmacies o Ownership Types Public Private o Geographical Locations Urban Rural o Others • Retail Pharmacies o Store Formats Chain Pharmacies Independent Pharmacies o Geographical Locations Urban Rural o Others • Online Pharmacies o Service Models Direct-to-Consumer B2B Distribution o Others